WO1995035276B1 - Metalloproteinase inhibitors - Google Patents

Metalloproteinase inhibitors

Info

Publication number
WO1995035276B1
WO1995035276B1 PCT/GB1995/001465 GB9501465W WO9535276B1 WO 1995035276 B1 WO1995035276 B1 WO 1995035276B1 GB 9501465 W GB9501465 W GB 9501465W WO 9535276 B1 WO9535276 B1 WO 9535276B1
Authority
WO
WIPO (PCT)
Prior art keywords
alk
group
conh
amended
hydrogen
Prior art date
Application number
PCT/GB1995/001465
Other languages
French (fr)
Other versions
WO1995035276A1 (en
Filing date
Publication date
Priority claimed from GB9412514A external-priority patent/GB9412514D0/en
Priority claimed from GBGB9506107.3A external-priority patent/GB9506107D0/en
Priority to DK95922639T priority Critical patent/DK0766665T3/en
Priority to NZ288299A priority patent/NZ288299A/en
Priority to US08/765,146 priority patent/US6022898A/en
Priority to AU27466/95A priority patent/AU690703B2/en
Application filed filed Critical
Priority to JP8501848A priority patent/JPH10507158A/en
Priority to DE69511089T priority patent/DE69511089T2/en
Priority to EP95922639A priority patent/EP0766665B1/en
Priority to GB9623675A priority patent/GB2303850B/en
Publication of WO1995035276A1 publication Critical patent/WO1995035276A1/en
Publication of WO1995035276B1 publication Critical patent/WO1995035276B1/en
Priority to US09/243,131 priority patent/US6124333A/en
Priority to GR990402229T priority patent/GR3031143T3/en

Links

Abstract

Compounds of general formula (II), wherein X is a hydroxamic or carboxylic acid group, Y is sulphonyl and R1 and R2 as defined in the claims are matrix metalloproteinase inhibitors.

Claims

39
AMENDED CLAIMS
[received by the International Bureau on 11 December 1995 (11.12.95); original claim 1 amended; remaining claims unchanged (1 page)]
A compound of general formula (II)
Figure imgf000003_0001
wherein
X represents a -CONHOH group;
R1 represents:
(i) the characterising side chain of a natural or non-natural alpha amino acid, in which any functional group present may be protected;
R2 represents a group Z -Q-W- where Z1 represents hydrogen or an optionally substituted aryl, heteroaryl, non-aromatic heterocyclyl, cycloalkyl, or cycloalkenyl group, and
(i) (except when Z1 is 4-methoxyphenyl) -Q-W- taken together represent a bond or
(ii) Q represents -O- or -S- and W represents a divalent C^C^ straight or branched alkyl or C2-C20 alkenyl group which
(a) may be interrupted by one or more non-adjacent ether or thioether linkages or -N(RX)- groups wherein Rx is hydrogen, or C C6 alkyl, and/or
(b) may carry one or more substituents selected from -OH, -SH, -O(Alk), -S(Alk), halogen, -NH2, -NH(Alk), -N(Alk)2, -C02H, -C02(Alk), -CO(Alk), -CHO, -CONH2, -CONH(Alk), -CON(Alk)2, -
PCT/GB1995/001465 1994-06-22 1995-06-22 Metalloproteinase inhibitors WO1995035276A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB9623675A GB2303850B (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors
EP95922639A EP0766665B1 (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors
NZ288299A NZ288299A (en) 1994-06-22 1995-06-22 Substituted (hetero)aryl-sulphonylaminomethyl-hydroxamic acid and medicaments
US08/765,146 US6022898A (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors
AU27466/95A AU690703B2 (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors
DK95922639T DK0766665T3 (en) 1994-06-22 1995-06-22 metalloproteinase
JP8501848A JPH10507158A (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors
DE69511089T DE69511089T2 (en) 1994-06-22 1995-06-22 METALLOPROTEINASE INHIBITORS
US09/243,131 US6124333A (en) 1995-06-22 1999-02-03 Metalloproteinase inhibitors
GR990402229T GR3031143T3 (en) 1994-06-22 1999-09-02 Metalloproteinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9412514.3 1994-06-22
GB9412514A GB9412514D0 (en) 1994-06-22 1994-06-22 Metalloproteinase inhibitors
GB9506107.3 1995-03-24
GBGB9506107.3A GB9506107D0 (en) 1995-03-24 1995-03-24 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
WO1995035276A1 WO1995035276A1 (en) 1995-12-28
WO1995035276B1 true WO1995035276B1 (en) 1996-01-18

Family

ID=26305102

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1995/001464 WO1995035275A1 (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors
PCT/GB1995/001465 WO1995035276A1 (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001464 WO1995035275A1 (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors

Country Status (17)

Country Link
US (4) US5962529A (en)
EP (2) EP0766665B1 (en)
JP (2) JPH10507158A (en)
CN (1) CN1151157A (en)
AT (2) ATE182581T1 (en)
AU (2) AU695507B2 (en)
CA (2) CA2193692A1 (en)
DE (2) DE69511089T2 (en)
DK (2) DK0766665T3 (en)
ES (2) ES2133785T3 (en)
FI (1) FI965153A (en)
GB (2) GB2303629B (en)
GR (2) GR3031143T3 (en)
NO (1) NO965515L (en)
NZ (2) NZ288298A (en)
PT (1) PT766664E (en)
WO (2) WO1995035275A1 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
AU695507B2 (en) * 1994-06-22 1998-08-13 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
KR980009238A (en) 1995-07-28 1998-04-30 우에노 도시오 Sulfonyl amino acid derivative
ATE226936T1 (en) * 1995-08-08 2002-11-15 Ono Pharmaceutical Co HYDROXAMIC ACID DERIVATIVES USABLE FOR INHIBITING GELATINASE
PT861236E (en) 1995-11-13 2002-07-31 Hoechst Ag ALPHA-IMINOHIDOXAMICOS AND N-SUBSTITUTED CARBOXYLIC ACID ACIDS AND HETEROCYCLICS
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
CN1542002A (en) * 1995-12-08 2004-11-03 ������ҩ�����޹�˾ Inhibitors of metalloproteinase, pharmaceutical compositions containing them, their pharmaceutical application and methods and intermediate compounds for their preparation
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
IL125378A0 (en) * 1996-01-23 1999-03-12 Shionogi & Co Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
FR2748026B1 (en) * 1996-04-26 1998-06-05 Adir NOVEL METALLOPROTEASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PT901466E (en) * 1996-05-17 2002-04-29 Warner Lambert Co BIPHENYLSULFONAMIDES AS MATRIX METALOPROTEINASE INHIBITORS
DE69731642T2 (en) * 1996-08-16 2005-12-01 Warner-Lambert Co. Llc BUTTERIC ACID MATRIX METALOPROTEINASE INHIBITORS
BR9711223A (en) * 1996-08-23 1999-08-17 Pfizer Arylsulfonylaminohydroxic acid derivatives
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
ATE227274T1 (en) * 1996-08-28 2002-11-15 Procter & Gamble 1,3-DIHETEROCYCLIC METALLOPROTEASE INHIBITORS
JP3539736B2 (en) * 1996-08-28 2004-07-07 ザ プロクター アンド ギャンブル カンパニー Phosphinamides as substrate metalloprotease inhibitors
NZ334257A (en) * 1996-08-28 2000-11-24 Procter & Gamble Spirocyclic metalloprotease inhibitors
BR9712792A (en) * 1996-08-28 1999-12-14 Procter & Gamble Bidentate metalloprotease inhibitors.
TR199900382T2 (en) * 1996-08-28 1999-05-21 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors.
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
IL129147A0 (en) * 1996-10-16 2000-02-17 American Cyanamid Co The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
WO1998017645A1 (en) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998018754A1 (en) 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
AU720615B2 (en) * 1997-01-17 2000-06-08 Pharmacia & Upjohn Company Bis-sulfonomides hydroxamic acids as MMP inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
PT983267E (en) * 1997-03-04 2005-06-30 Pharmacia Corp SULFONAMIDE COMPOUNDS AMIDOAROMATICAS DE ACIDO HIDROXAMICO
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
NZ338082A (en) * 1997-04-01 2000-06-23 Agouron Pharma Metalloproteinase and Tumor Necrosis Factor-alpha convertase inhibitors, pharmaceutical compositions and their use in treating disease mediated by metalloproteinase activity.
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
DE19719621A1 (en) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarboxylic acids
EP0877019B1 (en) * 1997-05-09 2001-12-12 Hoechst Aktiengesellschaft Substituted diaminocarboxylic acid
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
SK262000A3 (en) 1997-07-22 2001-01-18 Shionogi & Co Therapeutic or prophylactic agent for glomerulopathy
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
EP0895988B1 (en) * 1997-08-08 2002-05-22 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
GB9801690D0 (en) * 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
HUP0101176A3 (en) 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
HUP0101837A3 (en) * 1998-02-19 2001-11-28 American Cyanamid Co Madison N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
HUP0102837A3 (en) 1998-07-16 2002-04-29 Sanofi Aventis Deutschland Phosphinous and phosphonic acid derivatives, their use medicaments containing the same and process for producing them
US6107337A (en) * 1998-08-06 2000-08-22 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
DE19851184A1 (en) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-arylsulfonylamino acid omega amides
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
EP1165530A2 (en) 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
AU764051B2 (en) 1999-03-03 2003-08-07 Procter & Gamble Company, The Alkenyl- and alkynyl-containing metalloprotease inhibitors
EP1041072B1 (en) 1999-03-31 2003-07-16 Pfizer Products Inc. Dioxocyclopentyl hydroxamic acids
JP3892296B2 (en) 1999-09-10 2007-03-14 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitor
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
SI2014285T1 (en) 1999-11-26 2010-08-31 Shionogi & Co NPYY5 antagonists
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
JP2003528082A (en) * 2000-03-21 2003-09-24 ザ プロクター アンド ギャンブル カンパニー Difluorobutyric acid metalloprotease inhibitor
RU2002128003A (en) * 2000-03-21 2004-02-27 Дзе Проктер Энд Гэмбл Компани (US) METALLOPROTEAZ INHIBITORS CONTAINING A CARBOCYCLIC SIDE CHAIN
SK12842002A3 (en) 2000-03-21 2003-02-04 The Procter And Gamble Company Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
BR0109353A (en) * 2000-03-21 2003-04-08 Procter & Gamble Heterocyclic Side Chain Containing Metalloprotease Inhibitors
US6495358B1 (en) 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
DE60114022T2 (en) 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit MATRIX METALOPROTEINASE INHIBITORS
ES2345977T3 (en) * 2001-03-14 2010-10-07 Novartis Ag AZACICLOALQUIL ACETIC ACID DERIVATIVES SUBSTITUTED FOR USE AS MMP INHIBITORS.
CA2446740A1 (en) * 2001-05-11 2002-11-21 Guilford Pharmaceuticals Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
DE60208792T2 (en) 2001-06-22 2006-08-31 Merck & Co., Inc. TYROSINE KINASE INHIBITORS
CA2464727A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU2003233154A1 (en) 2002-06-10 2003-12-22 Pfizer Inc. Metabolites of prinomastat and their sythesis
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
US20040192658A1 (en) * 2002-12-27 2004-09-30 Angiotech International Ag Compositions and methods of using collajolie
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7576222B2 (en) * 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US7928127B2 (en) 2005-05-19 2011-04-19 Notre Dame University Inhibitors of matrix metallaproteinases
CA2730708A1 (en) * 2008-07-14 2010-01-21 Novartis Ag Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
WO2012038944A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077998A (en) * 1975-10-28 1978-03-07 Morton-Norwich Products, Inc. Phthaloyl amino acid hydroxamic acids
US4885027A (en) * 1985-04-05 1989-12-05 Chevron Research Company Herbicidal arylmethylenesulfonamido-acetamide and thioacetamide derivatives
DK77487A (en) * 1986-03-11 1987-09-12 Hoffmann La Roche hydroxylamine
EP0320898A3 (en) * 1987-12-18 1989-08-16 Schering Corporation Processes and compounds useful for resolving 1-methyl-3-phenylpropylamine
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
KR927003520A (en) * 1990-12-03 1992-12-18 죤 에드워드 베리만 Peptidyl derivatives
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU695507B2 (en) * 1994-06-22 1998-08-13 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
PT901466E (en) * 1996-05-17 2002-04-29 Warner Lambert Co BIPHENYLSULFONAMIDES AS MATRIX METALOPROTEINASE INHIBITORS

Similar Documents

Publication Publication Date Title
WO1995035276B1 (en) Metalloproteinase inhibitors
WO1995035275B1 (en) Metalloproteinase inhibitors
TW200407287A (en) A sulfonated amine acid derivative and the metalloproteinase inhibitor containing it (I)
AU4831899A (en) 5-HT1F agonists
TW270116B (en)
BR9913255A (en) Compound, pharmaceutical composition, process for treating a metalloproteinase-mediated disease condition, process for preparing a compound, and use of a compound
IL126610A0 (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
SG52479A1 (en) Injection and injection kit containing omeprazole and its analogs
GB2303850A (en) Metalloproteinase inhibitors
ATE290590T1 (en) STABILIZATION OF PROTEINS IN SOLUTION
AU4774197A (en) Use of sibutramine analogues to lower lipid levels
UA66818C2 (en) A-HYDROXY, AMINO- AND HALODERIVATIVES OF b-SULFONYL HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES
ATE186624T1 (en) SPRAY DISINFECTANT PREPARATION
CA2063938A1 (en) Novel azadecalin amides and thioamides as inhibitors of cholesterol biosynthesis
WO2003007954A3 (en) Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
BR8602740A (en) PROCESS FOR THE PREPARATION OF ISOMERS AND DERIVATIVES AND PEPTIDES OF N-ALPHA (2-CYAN-2-ALCOXYMINE-ACETYL) -AMINO ACIDS, PESTICIDED COMPOSITES, PROCESSES FOR COMBATING PARASITES AND FUNGI AND FOR THE PREPARATION OF COMPOSITES
IE830807L (en) Phenoxyalkylcarboxylic acid derivatives
KR890011596A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for treating insomnia
DE60112309D1 (en) USE OF PERCARBAMIC ACID AND DIACYLPER CARBAMATES AND THEIR PREPARATIONS
AU5197599A (en) Fluorescent labelling reagents
DK0643690T3 (en) Desferrioxamine B salts as well as their use as orally active iron chelating agents
AU6117698A (en) Antiviral agents
BR0007499A (en) Compound
BR9813775A (en) Use of a compound, process for the treatment of a vascular headache condition, and, pharmaceutical composition suitable for use in the treatment of a vascular headache condition.
KR840006622A (en) Process for preparing 1-aroyl-5-oxo-2-pyrrolidine propanoic acid and esters thereof